Last updated: August 19, 2026, with current clinical-trial information, scientific references, reconstitution calculations and updated evidence on MOTS-c dosing.
Quick Answer: Is There an Established Human MOTS-c Dosage?
No officially established human MOTS-c dosage exists in the United States. MOTS-c is not an FDA-approved drug, and available published human studies mainly measure naturally occurring MOTS-c levels during exercise or disease states rather than testing a consumer dosing protocol. A recruiting Phase 2a ClinicalTrials.gov study lists investigational MOTS-c as a fixed once-daily subcutaneous injection for 12 weeks in adults with prediabetes and overweight/obesity, but the public record does not disclose the dose amount and has no posted results as of this update (NCT07505745).
The dosage charts and calculator examples below are therefore concentration and measurement tools. They can show how many milligrams or micrograms are present per mL after reconstitution, or how many U-100 syringe units correspond to a chosen research amount. They do not prove that any input amount is safe, effective, appropriate for weight loss, better for women, useful for bodybuilding, or medically recommended.
Existing internet protocols often mix together mouse research, unpublished clinic practice and arithmetic examples. This guide keeps those categories separate so readers can understand the math without mistaking it for medical dosing advice.
What Is MOTS-c?
MOTS-c stands for mitochondrial open reading frame of the 12S rRNA type-c. It is a 16-amino-acid mitochondrial-derived peptide encoded within the 12S rRNA region of mitochondrial DNA. Early mechanistic work reported that MOTS-c participates in cellular energy signaling, including pathways related to skeletal muscle metabolism, folate-purine metabolism and AMPK activation.
In a 2015 Cell Metabolism paper, Lee and colleagues reported that MOTS-c influenced glucose handling, insulin sensitivity and diet-induced obesity in mice, with skeletal muscle appearing to be a major target tissue (Lee et al.). A later Cell Metabolism study found that MOTS-c can move into the nucleus during metabolic stress and regulate stress-response gene expression in an AMPK-dependent way (Kim et al.). These findings are biologically interesting, but they are not the same as proof of a standard human dose or an approved treatment.
Human research is still early. Some studies show that endogenous MOTS-c changes after exercise or differs across clinical populations. For example, acute endurance exercise increased circulating mitochondrial-derived peptides in humans (Woodhead et al.), and a breast-cancer-survivor exercise study found changes in MOTS-c after a 16-week exercise program in one subgroup (Dieli-Conwright et al.). These studies do not administer MOTS-c as a drug.
MOTS-c Dosage Chart: What the Numbers Actually Represent
The safest way to read a MOTS-c dosage chart is to ask: where did this number come from? A number from a mouse injection study, a registered trial with undisclosed dose, a supplier vial label or a syringe calculation does not carry the same meaning.
| Dosage-related number | What it represents | Evidence/source type | What it does not prove |
|---|---|---|---|
| Fixed once-daily subcutaneous injection for 12 weeks | Regimen listed for an investigational MOTS-c arm in adults with prediabetes and overweight/obesity | ClinicalTrials.gov NCT07505745; recruiting, no posted results; public record does not disclose dose amount | Does not establish a public dosage, safety profile or efficacy result |
| 5 mg/kg/day in mice | Common preclinical research dose used in metabolic and muscle studies | Peer-reviewed animal research | Does not convert directly into a human dose and is not a recommendation |
| 15 mg/kg in young mice in some exercise-capacity experiments | Higher preclinical dose used in specific mouse performance experiments | Peer-reviewed animal research | Does not prove bodybuilding benefits or human performance enhancement |
| 5 mg, 10 mg or 40 mg vial | Total peptide amount in the vial before dilution | Product/vial quantity | Does not mean the whole vial is one dose |
| 1 mL, 2 mL, 3 mL or 4 mL diluent | Reconstitution volume used to create a concentration | Math and handling choice | Does not change the total peptide in the vial and does not determine an appropriate dose |
MOTS-c Dosage Per Day vs Per Week
There is not enough published human evidence to establish an optimal MOTS-c dose per day or per week. The most relevant active human trial record lists a once-daily fixed-dose subcutaneous regimen for 12 weeks, but it does not publicly state the dose amount (NCT07505745). Published human exercise studies measured endogenous MOTS-c levels; they did not test a daily or weekly dosing protocol.
That matters because many pages present daily weight-based dosing or weekly milligram schedules as if they were clinical standards. For MOTS-c, those numbers should be treated as experimental or clinic/community practices unless they are tied to a verifiable research protocol or qualified medical oversight. A calculator can divide an amount by days or injections, but it cannot decide whether that amount should be used.
MOTS-c Dosage Calculator: What It Can and Cannot Calculate
A MOTS-c dosage calculator is useful for vial concentration math. It can calculate concentration per mL, milligrams per syringe unit and the draw volume for a selected research amount. It cannot determine a medically appropriate MOTS-c dosage.
If you need an interactive calculator, use the Peptides Unleashed peptide calculator. Use it as a measurement tool only. Entering a number into a calculator does not make that number safe, effective or evidence-based.
Basic MOTS-c calculator formulas
- Total peptide in mcg: vial mg x 1,000
- Concentration per mL: total mcg divided by mL of diluent
- mL to draw: selected mcg amount divided by mcg per mL
- U-100 syringe units: mL to draw x 100
Example: a 10 mg vial contains 10,000 mcg. If 2 mL bacteriostatic water is added, the concentration is 5,000 mcg/mL. A selected 500 mcg research amount would equal 0.1 mL, or 10 units on a U-100 insulin syringe. This is only a math example, not a dose recommendation.
MOTS-c 10 mg Reconstitution and Dosage Calculator
A 10 mg MOTS-c vial contains 10,000 mcg total peptide. Adding more bacteriostatic water lowers the concentration per mL; it does not reduce the total amount of MOTS-c in the vial.
Some readers search for a MOTS-c 10 mg dosage calculator because they want to know how much to draw from a syringe. The table below answers only the concentration question. The chosen research amount must come from an appropriate protocol or qualified clinician, not from the vial size.
| 10 mg vial + diluent | Concentration | 100 mcg equals | 500 mcg equals | 1 mg equals |
|---|---|---|---|---|
| 10 mg + 1 mL | 10,000 mcg/mL | 0.01 mL / 1 unit | 0.05 mL / 5 units | 0.10 mL / 10 units |
| 10 mg + 2 mL | 5,000 mcg/mL | 0.02 mL / 2 units | 0.10 mL / 10 units | 0.20 mL / 20 units |
| 10 mg + 3 mL | 3,333 mcg/mL | 0.03 mL / 3 units | 0.15 mL / 15 units | 0.30 mL / 30 units |
| 10 mg + 4 mL | 2,500 mcg/mL | 0.04 mL / 4 units | 0.20 mL / 20 units | 0.40 mL / 40 units |
Readers comparing vial options may encounter a MOTS-c 10 mg product page on Fitaminos. Treat product pages as commercial information, not as scientific evidence for a dose.
MOTS-c 40 mg Dosage Chart and Reconstitution
A 40 mg MOTS-c vial means the vial contains 40,000 mcg total peptide. It does not mean 40 mg is an administered amount. Larger vials make concentration math more important because a small syringe volume can contain a large quantity of peptide.
| 40 mg vial + diluent | Concentration | 100 mcg equals | 500 mcg equals | 1 mg equals |
|---|---|---|---|---|
| 40 mg + 2 mL | 20,000 mcg/mL | 0.005 mL / 0.5 unit | 0.025 mL / 2.5 units | 0.05 mL / 5 units |
| 40 mg + 4 mL | 10,000 mcg/mL | 0.01 mL / 1 unit | 0.05 mL / 5 units | 0.10 mL / 10 units |
| 40 mg + 8 mL | 5,000 mcg/mL | 0.02 mL / 2 units | 0.10 mL / 10 units | 0.20 mL / 20 units |
For very concentrated solutions, small measurement errors can become meaningful. This is one reason concentration arithmetic should be separated from medical decision-making.
MOTS-c Dosage for Women
Credible evidence does not currently establish a separate MOTS-c dosage for women. Some human studies include women or examine sex-related associations, but those studies do not provide a validated female-specific dosing protocol.
A study in breast cancer survivors found that a 16-week aerobic and resistance exercise intervention changed plasma MOTS-c in non-Hispanic White participants but not Hispanic participants. That research measured endogenous MOTS-c after exercise; it did not administer MOTS-c or test a dose for women. A 2024 iScience paper also reported sex-specific associations for a naturally occurring MOTS-c variant and cardiometabolic risk, but genetic association data are not dosage instructions.
Women searching for MOTS-c peptide dosage should be especially cautious with pages that invent lower or higher female protocols without clinical evidence. Body weight, pregnancy status, medications, endocrine conditions, cancer history and cardiometabolic disease can all matter clinically, but the MOTS-c literature does not yet translate those factors into an established dosing chart.
MOTS-c Dosage for Weight Loss
No MOTS-c dosage has been proven in published human trials to cause weight loss. The weight-loss interest comes mostly from animal and mechanistic research showing effects on metabolism, glucose handling, insulin sensitivity, fat metabolism or diet-induced obesity models.
In the 2015 Cell Metabolism study, MOTS-c treatment reduced obesity and insulin resistance in mice under specific experimental conditions. That is not the same as demonstrating weight loss in humans using a commercial peptide protocol. The recruiting Phase 2a study in adults with prediabetes and overweight/obesity may eventually provide more relevant human data, but results are not posted yet (NCT07505745).
Current evidence does not support a MOTS-c fat-loss protocol for humans. Human dosing, expected weight-loss magnitude, durability of any effect and long-term safety remain unestablished.
MOTS-c Dosage for Bodybuilding and Performance
MOTS-c bodybuilding dosage is not established by human performance trials. Exercise-related MOTS-c research is interesting, but it mostly concerns endogenous MOTS-c responses to exercise or animal models of muscle function and physical capacity.
Reynolds and colleagues reported that MOTS-c was exercise-induced and influenced age-dependent physical decline and muscle homeostasis in preclinical models; in the human portion, exercise changed MOTS-c expression and circulating levels in young men (Reynolds et al.). Another human study found that serum MOTS-c correlated with lower-body muscle strength in physically active adults, but correlation does not prove that taking MOTS-c improves strength (Skladany et al.).
Athletes should also treat anti-doping risk conservatively. The WADA Prohibited List includes a broad S0 category for substances that are not approved for therapeutic use in humans by a government regulatory health authority, along with separate categories for peptide hormones, growth factors, related substances and mimetics. MOTS-c may not be named in every public summary, but non-approved investigational substances can still create risk. Competitive athletes should check WADA, USADA or GlobalDRO before using any investigational peptide.
MOTS-c Reconstitution Explained
Reconstitution means adding a sterile diluent to a lyophilized, or freeze-dried, peptide powder so it becomes a measurable liquid solution. For MOTS-c, online instructions often mention bacteriostatic water, milligrams, micrograms, milliliters and U-100 syringe units. These are measurement terms, not proof of an appropriate dose.
Key terms
- mg: milligram. One mg equals 1,000 mcg.
- mcg: microgram. Many peptide calculations convert vial mg into mcg for smaller measurements.
- mL: milliliter. This measures liquid volume.
- Concentration: the amount of peptide per mL after mixing.
- U-100 syringe unit: on a U-100 insulin syringe, 100 units equals 1 mL, so 10 units equals 0.1 mL.
- Bacteriostatic water: sterile water with a preservative, commonly benzyl alcohol, used in some multi-dose vial contexts. It does not make a non-approved peptide approved or guarantee stability.
Changing the amount of bacteriostatic water changes concentration. It does not change the total peptide in the vial. A 10 mg vial still contains 10 mg whether it is mixed with 1 mL, 2 mL or 4 mL.
Storage and stability
Storage instructions should come from the product’s certificate of analysis, manufacturer documentation, pharmacy instructions or research protocol. In general peptide-handling practice, lyophilized peptides are commonly protected from heat, light and moisture; reconstituted solutions are usually refrigerated. However, MOTS-c-specific, product-independent stability data are limited, so there is no well-supported universal number of days that applies to every reconstituted MOTS-c product. Do not use cloudy, discolored or contaminated-looking material.
Timing, Frequency and Cycle Length
There is not enough human evidence to establish optimal MOTS-c timing, frequency or cycle length. Questions such as morning versus evening, before exercise, daily versus non-consecutive days, or two-week versus twelve-week cycles are not answered by published human dosing trials.
The active Phase 2a record uses a once-daily subcutaneous regimen for 12 weeks in a controlled investigational setting. Preclinical studies have used different schedules, including daily mouse dosing and intermittent mouse treatment in aging/exercise experiments. These designs answer specific research questions; they do not create a general consumer protocol.
Safety, Side Effects and Limitations
The long-term safety of MOTS-c administration in humans is not established. The FDA has identified uncertainty concerning human safety and potential issues such as immunogenicity and peptide-related impurities for certain bulk substances including MOTS-c; that does not prove MOTS-c is dangerous, but it is a regulatory safety concern (FDA). That is the most important safety point. Existing human publications largely involve measuring endogenous MOTS-c, and the recruiting Phase 2a trial has no posted results yet. Animal and cell studies can guide hypotheses, but they cannot fully predict human adverse effects.
Potential concerns include injection-site reactions, contamination risk with any multi-dose vial, dosing errors caused by concentration confusion, unknown long-term effects, unknown effects in pregnancy or breastfeeding, and uncertain interactions in people with endocrine, metabolic, cardiovascular, kidney, liver, cancer or autoimmune conditions. Those concerns are not proof of harm in every case; they are evidence gaps that matter because MOTS-c is not an established approved therapy.
People with medical conditions, athletes subject to anti-doping rules, and anyone taking prescription medications should not rely on internet protocols. Professional guidance is appropriate when an investigational peptide intersects with health status, sports eligibility or regulated medical care.
MOTS-c Research Evidence Table
| Study/source | Human/animal/in vitro | Population/model | Intervention or exposure | Main outcome | What it does not prove |
|---|---|---|---|---|---|
| Lee et al., Cell Metabolism, 2015 | Animal and cell research | Mouse metabolic models; cultured cells | MOTS-c treatment in experimental models | Reported improved metabolic homeostasis, insulin sensitivity and obesity-related outcomes in mice | Does not establish a human dose or approved treatment |
| Kim et al., Cell Metabolism, 2018 | Cell/mechanistic research | Cells under metabolic stress | MOTS-c localization and gene regulation experiments | MOTS-c translocated to the nucleus and regulated stress-response genes | Does not define clinical dosing or outcomes |
| Reynolds et al., Nature Communications, 2021 | Animal plus human exercise biology | Mice; young healthy men in exercise study | Preclinical MOTS-c treatment; human exercise exposure | Reported effects on mouse physical capacity and exercise-related MOTS-c changes in humans | Does not prove a bodybuilding protocol or human administered dose |
| Woodhead et al., 2021 | Human exercise study | Adults randomized to endurance, resistance or control session | Exercise; no MOTS-c administration | Endurance exercise increased humanin and showed a trend for MOTS-c | Does not test MOTS-c dosing |
| Dieli-Conwright et al., 2021 | Human exercise intervention | Hispanic and non-Hispanic White breast cancer survivors | 16-week exercise intervention; no MOTS-c administration | MOTS-c increased in one subgroup and associated with metabolic changes | Does not establish MOTS-c dosage for women |
| NCT07505745, ClinicalTrials.gov | Human interventional trial registry | Adults with prediabetes and overweight/obesity | Investigational MOTS-c fixed once-daily subcutaneous injection for 12 weeks | Recruiting; no posted results as of this update | Does not publicly disclose the dose or establish efficacy |
MOTS-c Dosage FAQ
What is the typical MOTS-c dose in research?
Published MOTS-c research includes preclinical mouse doses such as 5 mg/kg/day in metabolic experiments and other animal schedules in exercise and aging models. Available published human studies mostly measure endogenous MOTS-c rather than administering it. A Phase 2a trial uses fixed once-daily subcutaneous MOTS-c, but the public record does not disclose the amount.
Is MOTS-c taken daily?
There is no established daily MOTS-c dosage for general human use. A current ClinicalTrials.gov record for adults with prediabetes and overweight/obesity lists investigational MOTS-c as a fixed once-daily subcutaneous injection for 12 weeks, but it has no posted results and does not publish the dose amount.
What is the MOTS-c dosage per week?
No evidence-based weekly MOTS-c dosage has been established for humans. Weekly totals found online often come from clinic-style or community protocols, not from published human dose-finding studies. A weekly amount can be calculated mathematically from a selected daily amount, but the calculation does not validate the input dose.
Is there a different MOTS-c dosage for women?
Current evidence does not establish a different MOTS-c dosage for women. Some human studies involving women measure endogenous MOTS-c responses to exercise or associations with metabolic markers, but they do not test administered MOTS-c dosing. Female-specific protocols should not be invented without clinical evidence.
What MOTS-c dosage has been studied for weight loss?
Weight-related MOTS-c evidence is mostly preclinical. Mouse studies reported effects on diet-induced obesity and insulin resistance, but published human trials have not yet shown a MOTS-c dose that reliably causes weight loss. The active Phase 2a study in overweight/obesity and prediabetes may provide future data, but results are not posted.
What does the research say about MOTS-c for bodybuilding?
Research does not establish a MOTS-c bodybuilding dosage. Animal studies and human exercise-biology studies suggest MOTS-c is connected with muscle metabolism and exercise responses, but that is not proof that taking MOTS-c improves strength, hypertrophy or performance in athletes.
How do you calculate a MOTS-c dose?
For measurement math, convert vial mg to mcg, divide by the amount of diluent to get mcg per mL, then divide the selected mcg amount by concentration to get mL. On a U-100 syringe, multiply mL by 100 to estimate units. This does not determine whether the selected amount is medically appropriate.
How do you calculate a 10 mg MOTS-c vial?
A 10 mg vial contains 10,000 mcg. If mixed with 2 mL bacteriostatic water, the concentration is 5,000 mcg/mL. At that concentration, 500 mcg equals 0.1 mL, or 10 units on a U-100 syringe. Different diluent volumes change concentration, not total peptide.
How much bacteriostatic water is used for a MOTS-c vial?
There is no universal MOTS-c diluent volume that is medically required by published human evidence. Common calculator examples use 1 mL, 2 mL, 3 mL or 4 mL because those volumes create easy concentrations. The correct handling volume should come from the manufacturer, pharmacy, research protocol or clinician.
What is the difference between 5 mg, 10 mg and 40 mg MOTS-c vials?
The difference is total peptide quantity in the vial: 5 mg equals 5,000 mcg, 10 mg equals 10,000 mcg, and 40 mg equals 40,000 mcg. Vial size is not the same as dose. Concentration depends on how much diluent is added.
Does changing bacteriostatic-water volume change the amount of MOTS-c?
No. Changing bacteriostatic-water volume changes concentration, not total peptide. A 10 mg vial still contains 10 mg after adding 1 mL or 2 mL. The 1 mL version is more concentrated, so each syringe unit contains more MOTS-c.
Does MOTS-c need refrigeration?
Storage instructions should follow the product label, certificate of analysis, pharmacy instructions or research protocol. In general peptide handling, lyophilized peptides are protected from heat, light and moisture, and reconstituted solutions are commonly refrigerated at 2–8°C. MOTS-c-specific universal stability instructions are not established by FDA-approved labeling.
How long does reconstituted MOTS-c remain stable?
No FDA-approved MOTS-c label establishes a universal post-reconstitution stability period. Many peptide suppliers provide handling windows, but those can vary by formulation, sterility, diluent, container and storage conditions. Treat product-specific documentation as more relevant than generic internet claims, and discard material that appears cloudy, discolored or contaminated.
How long has MOTS-c been studied in humans?
Human MOTS-c research has appeared mainly as exercise, observational and biomarker research, with studies measuring circulating or tissue MOTS-c rather than administering it as a therapy. A Phase 2a interventional trial in adults with prediabetes and overweight/obesity began in 2026; no results were posted as of the article’s August 19, 2026 update.
Scientific References
- Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism. 2015. Full text.
- Kim KH, Son JM, Benayoun BA, Lee C. The mitochondrial-encoded peptide MOTS-c translocates to the nucleus to regulate nuclear gene expression in response to metabolic stress. Cell Metabolism. 2018. PubMed.
- Reynolds JC, Lai RW, Woodhead JST, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nature Communications. 2021. PubMed.
- Woodhead JST, D’Souza RF, Hedges CP, et al. Acute endurance exercise stimulates circulating levels of mitochondrial-derived peptides in humans. American Journal of Physiology-Endocrinology and Metabolism. 2021. PubMed.
- Dieli-Conwright CM, et al. Effect of aerobic and resistance exercise on the mitochondrial peptide MOTS-c in Hispanic and Non-Hispanic White breast cancer survivors. 2021. Full text.
- Skladany L, et al. MOTS-c serum concentration positively correlates with lower-body muscle strength and is not related to maximal oxygen uptake: a preliminary study. 2023. PubMed.
- Yoshida M, et al. MOTS-c modulates skeletal muscle function by directly binding and activating CK2. iScience. 2024. PubMed.
- ClinicalTrials.gov. MOTS-c for Improving Insulin Sensitivity in Adults With Prediabetes and Overweight/Obesity (NCT07505745). ClinicalTrials.gov.
- U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding May Present Significant Safety Risks. FDA.
- World Anti-Doping Agency. The Prohibited List, in force January 1, 2026. WADA.
Where to source MOTS-c
Fit Aminos stocks research-grade MOTS-c.
We are affiliated with Fit Aminos and may earn from purchases made through this link.
